"Weight loss miracle drugs" GLP-1 class of drugs recently stirred the pharmaceutical industry again. Novo Nordisk has announced the early termination of the Phase 3 study FLOW, a GLP-1 drug called Simeaglutide, in patients with renal insufficiency type 2 diabetes and chronic kidney disease, because the drug has met certain preset criteria for efficacy. Affected by this news, on the 11th, the A-share weight loss drug sector rose sharply and continued to be strong today.